Mounjaro (tirzepatide) tracker
Educational reference for Mounjaro (tirzepatide). Use it inside TrackPep to log doses, side effects, and rotation sites.
Half-life
120 h
Tmax
24 h
Category
glp1
> PLACEHOLDER — pending clinical review by licensed pharmacist. Mounjaro is Eli Lilly's brand of tirzepatide for type 2 diabetes.
Mechanism
Mounjaro is a brand name for tirzepatide, a dual GIP and GLP-1 receptor agonist. See the tirzepatide entry for the full mechanism.
Research summary
Mounjaro is the tirzepatide product approved for type 2 diabetes (SURPASS program). For weight management, the tirzepatide product Zepbound is used. See the tirzepatide entry.
Dosing in the literature
Regimens are individualized and set by a prescribing clinician; they are outside the scope of this summary. See the tirzepatide entry.
Reported side effects
As a tirzepatide product, gastrointestinal effects are most commonly reported; prescribing information includes class warnings. See the tirzepatide entry. This is not a complete safety profile.
Stacking notes
See the tirzepatide entry. Combination with insulin or sulfonylureas raises hypoglycemia considerations.
Educational summary of published research. Not dosing guidance or medical advice.
Sources
- Mounjaro prescribing information · FDA prescribing information (2022)available via DailyMed; see tirzepatide entry
References
Track Mounjaro (tirzepatide) in TrackPep
Reconstitution calculator, interactive body-map rotation, side-effect timeline, weight trends, and a private log — all in one place. Free to try.